PRODUCT MONOGRAPH

ALEVE®

Naproxen Sodium Tablets USP
220 mg

ALEVE® Liquid Gels

Naproxen Sodium Capsules
220 mg

ALEVE® Back and Body Pain

Naproxen Sodium Capsules
220mg

Non-steroidal anti-inflammatory drug

Analgesic, Antipyretic

Bayer Inc. Consumer Care
2920 Matheson Boulevard East
Mississauga, ON L4W 5R6

Date of Revision:
January 8th, 2015

Control No.: 179420

© 2015, Bayer Inc.
Table of Contents

**PART I: HEALTH PROFESSIONAL INFORMATION**

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUMMARY PRODUCT INFORMATION</td>
<td>3</td>
</tr>
<tr>
<td>INDICATIONS AND CLINICAL USE</td>
<td>3</td>
</tr>
<tr>
<td>CONTRAINDICATIONS</td>
<td>4</td>
</tr>
<tr>
<td>WARNINGS AND PRECAUTIONS</td>
<td>4</td>
</tr>
<tr>
<td>ADVERSE REACTIONS</td>
<td>6</td>
</tr>
<tr>
<td>DRUG INTERACTIONS</td>
<td>10</td>
</tr>
<tr>
<td>DOSAGE AND ADMINISTRATION</td>
<td>11</td>
</tr>
<tr>
<td>OVERDOSAGE</td>
<td>12</td>
</tr>
<tr>
<td>ACTION AND CLINICAL PHARMACOLOGY</td>
<td>12</td>
</tr>
<tr>
<td>STORAGE AND STABILITY</td>
<td>13</td>
</tr>
<tr>
<td>SPECIAL HANDLING INSTRUCTIONS</td>
<td>13</td>
</tr>
<tr>
<td>DOSAGE FORMS, COMPOSITION AND PACKAGING</td>
<td>14</td>
</tr>
</tbody>
</table>

**PART II: SCIENTIFIC INFORMATION**

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHARMACEUTICAL INFORMATION</td>
<td>15</td>
</tr>
<tr>
<td>CLINICAL TRIALS</td>
<td>15</td>
</tr>
<tr>
<td>DETAILED PHARMACOLOGY</td>
<td>18</td>
</tr>
<tr>
<td>MICROBIOLOGY</td>
<td>18</td>
</tr>
<tr>
<td>TOXICOLOGY</td>
<td>18</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>22</td>
</tr>
</tbody>
</table>

**PART III: CONSUMER INFORMATION**

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
</table>

---

Page 2 of 38
ALEVE®
Naproxen Sodium Tablets

ALEVE® Liquid Gels
ALEVE® Back and Body Pain
Naproxen Sodium Capsules

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form / Strength</th>
<th>Clinically Relevant Nonmedicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>Caplets, Capsules, Tablets 220mg</td>
<td>For a complete listing, see the Dosage Forms, Composition and Packaging section of the Product Monograph</td>
</tr>
</tbody>
</table>

INDICATIONS AND CLINICAL USE

ALEVE®, ALEVE® Liquid Gels, and ALEVE® Back and Body Pain (naproxen sodium) are indicated for the reduction of fever and the treatment of pain:

- ALEVE® is clinically proven to relieve arthritis pain. ALEVE® relieves the daily pain and stiffness of arthritis. ALEVE® relieves morning stiffness and arthritis pain at rest, on passive motion, on weight bearing, pain experienced day or night due to arthritis
- ALEVE® helps relieve the night pain associated with arthritis
- ALEVE® relieves the pain of inflammation
- ALEVE® relieves the pain or stiffness of rheumatic or arthritic conditions
- ALEVE® relieves joint and body pain
- ALEVE® relieves muscular ache
- ALEVE® relieves the pain of muscle sprains and strains
- ALEVE® relieves backache
- ALEVE® relieves headache
- ALEVE® relieves migraine pain
- ALEVE® relieves the pain of menstrual cramps (dysmenorrhoea)
- ALEVE® relieves the pain of minor surgery
- ALEVE® relieves toothache
- ALEVE® relieves the pain of dental extractions
- ALEVE® relieves minor aches and pain associated with the common cold
CONTRAINDICATIONS

Naproxen sodium is contraindicated in patients

- who have previously exhibited allergy to naproxen sodium
- with known hypersensitivity to the active substance naproxen (including naproxen sodium) or any of the excipients in the caplets. For a complete listing, see the Dosage Forms, Composition and Packaging section of the product monograph
- with a history of asthma, urticaria, or allergic-type reactions after taking acetylsalicylic acid (ASA) or other NSAIDs (i.e. complete or partial syndrome of ASA-intolerance - rhinosinusitis, urticaria/angioedema, nasal polyps, asthma). Fatal anaphylactoid reactions have occurred in such individuals. Individuals with the above medical problems are at risk of a severe reaction even if they have taken NSAIDs in the past without any adverse reaction.
- with active peptic ulcers, a history of recurrent ulceration, or active gastrointestinal bleeding
- with inflammatory bowel disease.
- with severe liver impairment or active liver disease
- with severe renal impairment (creatinine clearance <30 mL/min or 0.5 mL/sec) or deteriorating renal disease (individuals with lesser degrees of renal impairment are at risk of deterioration of their renal function when prescribed NSAIDs and must be monitored)
- in women in their third trimester of pregnancy because of risk of premature closure of the ductus arteriosus and prolonged parturition.

WARNINGS AND PRECAUTIONS

General
Patients who are taking any other analgesic or anti-inflammatory drugs (including naproxen or naproxen sodium), steroids, diuretics or drugs that influence hemostasis.

Cardiovascular
Patients with severe cardiac impairment and a history of hypertension.

Gastrointestinal
Patients with a medical history of gastrointestinal disease including peptic ulceration. Pain of gastrointestinal origin is not an indication for naproxen sodium.

Hematologic
Patients with coagulation disturbances. Numerous studies have shown that concomitant use of NSAIDs and anti-coagulants increases the risk of bleeding. Concurrent therapy of ALEVE® with warfarin requires close monitoring of the international normalized ratio (INR). Even with therapeutic INR monitoring, increased bleeding may occur.

Neurologic
Some patients may experience drowsiness, dizziness, blurred vision vertigo, tinnitus, hearing loss, insomnia or depression with the use of NSAIDs such as ALEVE®. If patients experience
such adverse reactions, they should exercise caution in carrying out activities that require alertness, like driving or using machinery.

**Respiratory**
Patients with a medical history of asthma, rhinitis or nasal polyps.

**Skin**
Patients with a medical history of urticaria and angioedema.

**Fertility Impairment**
Naproxen, as with any drug known to inhibit cyclooxygenase/prostaglandin synthesis, may impair fertility and is not recommended in women attempting to conceive. In women who have difficulty conceiving or who are undergoing investigation of infertility, withdrawal of naproxen should be considered.

**Special Populations:**

**Geriatrics:**
Patients older than 65 years and frail or debilitated patients are more susceptible to a variety of adverse reactions from NSAIDs. The incidence of these adverse reactions increases with dose and duration of treatment. In addition, these patients are less tolerant to ulceration and bleeding. Most reports of fatal GI events are in this population. Older patients are also at risk of lower esophageal injury including ulceration and bleeding.

**Pregnant Women**
Caution should be exercised in prescribing ALEVE® during the first and second trimesters of pregnancy. As with other drugs of this type, naproxen sodium produces delay in parturition in animals and also affects the human fetal cardiovascular system (closure of the ductus arteriosus). Therefore, naproxen sodium should not be used unless clearly needed and when directed to do so by a doctor. The use of naproxen sodium in the first and second trimesters of pregnancy requires cautious balancing of the possible benefits and risks to the mother and fetus, especially during the first trimester.

Inhibition of prostaglandin synthesis may adversely affect pregnancy and/or the embryo/fetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation after use of a prostaglandin synthesis inhibitor in early pregnancy. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-fetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period.

**Nursing Women**
Naproxen has been found in the milk of lactating mothers. The use of naproxen sodium should therefore be avoided in women who are breast feeding unless clearly needed and directed to do so by a doctor.
**Pediatrics (< 12 years of age)**
Children under 12 should not take this drug, unless directed by a doctor. The safety in pediatric use has not been established.

**Persons on a Low Sodium Diet:**
One caplet contains 20 mg sodium, which is classified as low in sodium. A variety of Health Canada guidelines suggest that a diet low in sodium should be restricted to 2 g per day while the Sodium Collaborative Research group suggests that a low-sodium diet should be restricted to ≤ 1.2 g (50 mmol) per day.

**Monitoring and Laboratory Tests**
Naproxen sodium causes transient, dose-dependent modestly increased bleeding times. However, these values often do not exceed the upper limit of the reference range. Naproxen sodium may theoretically interfere with the urinary analyses of 17-ketogenic steroids and 5-hydroxy indoleacetic acid (5 HIAA).

**ADVERSE REACTIONS**

**Clinical Trial Adverse Drug Reactions**
*Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.*

The safety profile of ALEVE® was analysed through a meta-analysis of the clinical trials which were performed in the course of the ALEVE® clinical development program. The meta-analysis included a total of 46 studies, which satisfied the criteria of being randomized, placebo controlled, double-blind and used ALEVE® in single (SD, 220 mg or 440 mg pooled data), multiple (MD, 440 mg/day and 880 mg/day) or PRN (up to 880 mg/day) doses. In total 4623 subjects were treated with ALEVE® while 2659 took placebo. Fifty-two percent of subjects participated in SD trials, 20 % in MD trials all lasting for 7 days and the remaining 28% in PRN trials. They were predominantly Caucasian, slightly more women with a mean age between the 20s and 30s with exception of 422 patients from the arthritis studies with a mean age in the low 60s. The occurrence of all adverse events did not differ between ALEVE® and placebo, in the SD, MD or PRN trials. Moderate and severe events tended to occur less frequently in the subjects treated with ALEVE® MD compared to placebo, presumably due to concomitant treatment of naturally occurring headache. The data in table 1 shows the frequencies of adverse events that are > 1% from the meta-analysis. A thorough evaluation of gastrointestinal adverse events showed no difference between ALEVE® and placebo. There was no serious gastrointestinal adverse event (bleeding or perforation) or any case of anaphylaxis.
Table 1. Adverse events that occurred with ALEVE® (low dose short duration) with a frequency > 1% in clinical trials.

<table>
<thead>
<tr>
<th></th>
<th>ALEVE®</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n=4623</td>
</tr>
<tr>
<td></td>
<td>(%)</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td></td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>1.9%</td>
</tr>
<tr>
<td>Nausea</td>
<td>4.4%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>1.8%</td>
</tr>
<tr>
<td>Nervous System</td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>2.0%</td>
</tr>
<tr>
<td>Headache</td>
<td>4.9%</td>
</tr>
<tr>
<td>Somnolence</td>
<td>2.4%</td>
</tr>
<tr>
<td>Placebo</td>
<td></td>
</tr>
<tr>
<td></td>
<td>n=2659</td>
</tr>
<tr>
<td></td>
<td>(%)</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td></td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>1.8%</td>
</tr>
<tr>
<td>Nausea</td>
<td>4.8%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>2.4%</td>
</tr>
<tr>
<td>Nervous System</td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>2.1%</td>
</tr>
<tr>
<td>Headache</td>
<td>6.8%</td>
</tr>
<tr>
<td>Somnolence</td>
<td>1.5%</td>
</tr>
</tbody>
</table>

**Less Common Clinical Trial Adverse Drug Reactions (<1%)**

**Gastrointestinal:**
- Constipation
- Diarrhea

**Other**
- Allergic reactions
- Edema
- Rash/pruritus
### Post-Market Adverse Drug Reactions

Table 2. The following post-marketing adverse drug reactions have been observed for OTC naproxen sodium and/or solely for prescription dosages (higher dose and/or longer duration) of naproxen/naproxen sodium.

<table>
<thead>
<tr>
<th>System</th>
<th>Frequency</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Immune system</strong></td>
<td>Very rare</td>
<td>Anaphylaxis/anaphylactoid reactions</td>
</tr>
<tr>
<td></td>
<td>&lt; 0.01% and isolated reports</td>
<td></td>
</tr>
<tr>
<td><strong>Blood</strong></td>
<td>Very rare</td>
<td>hematopoietic disturbances (leukopenia, thrombocytopenia, agranulocytosis, aplastic anemia, eosinophilia, hemolytic anemia)</td>
</tr>
<tr>
<td></td>
<td>&lt; 0.01% and isolated reports</td>
<td></td>
</tr>
<tr>
<td><strong>Psychiatric</strong></td>
<td>Very rare</td>
<td>psychiatric disorders</td>
</tr>
<tr>
<td></td>
<td>&lt; 0.01% and isolated reports</td>
<td></td>
</tr>
<tr>
<td><strong>Nervous</strong></td>
<td>Common</td>
<td>dizziness, headache, lightheadedness</td>
</tr>
<tr>
<td></td>
<td>≥ 1% - &lt; 10%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>drowsiness, insomnia, somnolence</td>
</tr>
<tr>
<td></td>
<td>≥ 0.1% - &lt; 1%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Very rare</td>
<td>aseptic meningitis, cognitive dysfunction, convulsions</td>
</tr>
<tr>
<td></td>
<td>&lt; 0.01% and isolated reports</td>
<td></td>
</tr>
<tr>
<td><strong>Eye</strong></td>
<td>Very rare</td>
<td>visual disturbance, corneal opacity, papillitis, retrolublar optic neuritis, papilledema</td>
</tr>
<tr>
<td></td>
<td>&lt; 0.01% and isolated reports</td>
<td></td>
</tr>
<tr>
<td><strong>Ear &amp; labyrinth</strong></td>
<td>Uncommon</td>
<td>vertigo</td>
</tr>
<tr>
<td></td>
<td>≥ 0.1% - &lt; 1%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Very rare</td>
<td>hearing impairment, tinnitus</td>
</tr>
<tr>
<td></td>
<td>&lt; 0.01% and isolated reports</td>
<td></td>
</tr>
<tr>
<td><strong>Cardiac</strong></td>
<td>Very rare</td>
<td>congestive heart failure, hypertension, pulmonary edema</td>
</tr>
<tr>
<td></td>
<td>&lt; 0.01% and isolated reports</td>
<td></td>
</tr>
<tr>
<td><strong>Vascular</strong></td>
<td>Very rare</td>
<td>vasculitis</td>
</tr>
<tr>
<td></td>
<td>&lt; 0.01% and isolated reports</td>
<td></td>
</tr>
<tr>
<td><strong>Respiratory</strong></td>
<td>Very rare</td>
<td>dyspnea, asthma, eosinophilic pneumonitis</td>
</tr>
<tr>
<td></td>
<td>&lt; 0.01% and isolated reports</td>
<td></td>
</tr>
<tr>
<td><strong>Gastrointestinal</strong></td>
<td>Common</td>
<td>dyspepsia, nausea, heartburn, abdominal pain</td>
</tr>
<tr>
<td></td>
<td>≥ 1% - &lt; 10%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>diarrhea, constipation, vomiting</td>
</tr>
<tr>
<td></td>
<td>≥ 0.1% - &lt; 1%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rare</td>
<td>peptic ulcers without or with bleeding or perforation, gastrointestinal bleeding, hematemesis, melena</td>
</tr>
<tr>
<td></td>
<td>≥ 0.01% - &lt; 0.1%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Very rare</td>
<td>pancreatitis, colitis, aphthous ulcers, stomatitis, esophagitis, intestinal ulcerations</td>
</tr>
<tr>
<td></td>
<td>&lt; 0.01% and isolated reports</td>
<td></td>
</tr>
</tbody>
</table>
Severe allergic ADRs are very rare events, which are more likely to occur in subjects who have experienced allergic reactions previously. In short term use of naproxen sodium occurrence of GI ulcers/bleeding/perforation are rare events.

The adverse drug reactions seen during short term use of naproxen sodium are normally mild and disappear after discontinuing the drug. The most common ADRs for OTC naproxen sodium and/or solely for prescription doses (higher dose and or longer duration) are dizziness, headache, light-headedness, dyspepsia, nausea, heartburn, and abdominal pain. Uncommonly drowsiness, insomnia, and skin rashes are encountered. Peripheral edemas are rare events. Other ADRs are very rare and/or observed through isolated reports only. The adverse events are common to all NSAIDs as a class; there is no adverse event that is specific for naproxen alone.

<table>
<thead>
<tr>
<th><strong>Hepatobiliary</strong></th>
<th>Very rare</th>
<th>hepatitis, icterus</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt; 0.01% and isolated reports</td>
<td></td>
</tr>
<tr>
<td>Skin &amp; subcutaneous tissue</td>
<td>Uncommon</td>
<td>exanthema (rash), pruritus, urticaria</td>
</tr>
<tr>
<td></td>
<td>≥ 0.1% - &lt; 1%</td>
<td></td>
</tr>
<tr>
<td>Rare</td>
<td>angioneurotic edema</td>
<td></td>
</tr>
<tr>
<td>Very rare</td>
<td>alopecia (usually reversible), photosensitivity, porphyria, exudative erythema multiforme, epidermal necrolysis, erythema nodosum, fixed drug eruption, lichen planus, pustular reaction, skin rashes, Systemic Lupus Erythematosus, Stevens-Johnson syndrome, photosensitivity reactions including porphyria cutanea tarda (“pseudoporphyria”) or epidermolysis bullosa</td>
<td></td>
</tr>
<tr>
<td>Renal &amp; urinary</td>
<td>Rare</td>
<td>renal impairment</td>
</tr>
<tr>
<td></td>
<td>≥ 0.01% - &lt; 0.1%</td>
<td></td>
</tr>
<tr>
<td>Very rare</td>
<td>interstitial nephritis, renal papillary necrosis, nephrotic syndrome, renal failure, renal disease</td>
<td></td>
</tr>
<tr>
<td>Pregnancy</td>
<td>Very rare</td>
<td>Induction of labour</td>
</tr>
<tr>
<td></td>
<td>&lt; 0.01% and isolated reports</td>
<td></td>
</tr>
<tr>
<td>Congenital</td>
<td>Very rare</td>
<td>Closure of ductus arteriosus, orofacial clefts as an isolated report</td>
</tr>
<tr>
<td></td>
<td>&lt; 0.01% and isolated reports</td>
<td></td>
</tr>
<tr>
<td>Reproductive</td>
<td>Very rare</td>
<td>female infertility</td>
</tr>
<tr>
<td></td>
<td>&lt; 0.01% and isolated reports</td>
<td></td>
</tr>
<tr>
<td>General disorders</td>
<td>Rare</td>
<td>peripheral edema, particular in patients with hypertension or kidney failure, pyrexia</td>
</tr>
<tr>
<td></td>
<td>≥ 0.01% - &lt; 0.1%</td>
<td></td>
</tr>
<tr>
<td>Investigations</td>
<td>Very rare</td>
<td>raised serum creatinine, abnormal liver function test</td>
</tr>
<tr>
<td></td>
<td>&lt; 0.01% and isolated reports</td>
<td></td>
</tr>
</tbody>
</table>
DRUG INTERACTIONS

Overview
During short term use of naproxen sodium, interactions with the following medications could be of clinical significance.

Drug-Drug Interactions

The drugs listed in table 3 are based on either drug interaction case reports or studies.

<table>
<thead>
<tr>
<th>Table 3 - Established or Potential Drug-Drug Interactions Proper Name</th>
<th>Effect</th>
<th>Clinical comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclosporine</td>
<td>cyclosporin concentrations may increase, which could induce nephrotoxicity</td>
<td>These patients should be monitored adequately.</td>
</tr>
<tr>
<td>Lithium</td>
<td>in some patients lithium concentrations may increase, which could induce nausea, polydipsia, polyuria, tremor, confusion</td>
<td>These patients should be monitored adequately</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>if weekly methotrexate intake exceeds 15 mg, methotrexate concentrations may increase which could induce blood dyscrasia, nephrotoxicity, mucosal ulcerations</td>
<td>These patients should be monitored adequately</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>adds to the risk of gastro-intestinal bleeding</td>
<td>Should be avoided; however, effects may be minimised by using the lowest effective dose for the shortest duration necessary.</td>
</tr>
<tr>
<td>Low dose ASA (81mg to 325mg daily, for cardiovascular protection e.g. ASPIRIN® 81mg)</td>
<td>Can add to the risk of gastro-intestinal bleeding</td>
<td>These patients should be monitored adequately</td>
</tr>
<tr>
<td>Anticoagulants</td>
<td>adds to the risk of gastro-intestinal bleeding</td>
<td>These patients should be monitored adequately</td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td>adds to the risk of gastro-intestinal bleeding</td>
<td>These patients should be monitored adequately</td>
</tr>
<tr>
<td>Diuretics, antihypertensive drugs including ACE Inhibitors, β blockers</td>
<td>the diuretic and antihypertensive efficacy, particular in patients with pre-existing nephropathy, may be reduced</td>
<td>These patients should be monitored adequately. Concomitant use with anti-diuretics may increase risk of congestive heart failure.</td>
</tr>
</tbody>
</table>

In a recent (2005) American case-control study, labelled, short term use of OTC naproxen or OTC ibuprofen was not associated with GI risk nor was there any detectable interaction with ASA at this dose level; furthermore there was no difference between OTC naproxen or OTC ibuprofen. An increased risk could be attributed with concomitant use of ASA and high dose NSAIDs; however, the numbers of exposed cases were small.

Another recent (2006) American retrospective database study found an odds ratio of 2.07 (1.23 – 3.49) for GI complications with concomitant use of low dose ASA and OTC-dose naproxen; for comparison, this ratio was 3.36 (2.36 – 4.80) in subjects taking OTC-dose ibuprofen and low dose ASA; the corresponding ratio for naproxen as mono-therapy was 1.54 (1.04-2.28) which is not significantly different from the combined therapy. The corresponding ratio for ibuprofen as mono-therapy was 1.38 (1.07-1.78) which is significantly lower than the combined therapy of ibuprofen and low dose ASA therapy.

Due to the nature of the study, information regarding the duration of naproxen and ibuprofen intake could not be collected. The findings are consistent with previous study results indicating increased GI risk in patients taking OTC-NSAIDS for longer terms or prescription NSAIDs.
while on low dose ASA.

Labelled, short term use of OTC naproxen together with low dose ASA was not associated with a detectable GI-risk; longer term use (mainly >10 days) of NSAIDs in OTC doses and concomitant ASA can increase the relative risk a little, adding however only very little absolute risk.

During short term use of naproxen sodium interactions of clinical significance do not seem to be relevant for the following medications: antacids, antidiabetics, hydantoines, probenecid, zidovudine.

**Drug-Food Interactions**
ALEVE® (Caplets): The absorption may be slightly delayed with a meal
ALEVE® Liquid Gels and ALEVE® Back and Body Pain (Capsules): Peak naproxen levels were reached at 1.4 hours on an empty stomach and at 3.7 hours with a meal.

**Drug-Herb Interactions**
Interactions with herbal products have not been established

**Drug-Laboratory Interactions**
Naproxen sodium causes transient, dose-dependent modestly increased bleeding times. However, these values often do not exceed the upper limit of the reference range. Naproxen sodium may theoretically interfere with the urinary analyses of 17-ketogenic steroids and 5-hydroxy indoleacetic acid (5 HIAA).

**DOSAGE AND ADMINISTRATION**

**Dosing Considerations**
- In self-medication, ALEVE® should only be used for a short term treatment period of up to five days for pain and 3 days for fever. Otherwise a doctor should be consulted.
- Each dose should be swallowed with a full glass of water and can be taken fasting or with meals and/or antacids. Absorption may be slightly delayed with meals.
- If symptoms change, a doctor should be consulted.
- The recommended dosage should be adhered to unless directed by a doctor.
- ALEVE® is as safe on the stomach as Tylenol Extra Strength 500 mg and Advil 200mg if the maximum daily dose and the recommended length of use for each product is not exceeded.
- ALEVE® provides non-prescription pain relief that lasts up to 12 hours with 1 pill.

**Recommended Dose and Dosage Adjustment**

**Adults (12-65 years):** 1 caplet/capsule every 8 - 12 hours. For individuals over 65 years, 1 caplet/capsule every 12 hours. Do not take more than 2 caplets/capsules in a 24 hour period. Drink a full glass of water with each dose.
**Under 12 years:** Children under 12 should not take this drug. The safety in pediatric use has not been established.

**OVERDOSAGE**
Significant overdose can be characterized by drowsiness, heartburn, indigestion, nausea and vomiting. A few patients have experienced convulsions but it is not clear if these were naproxen related. Some cases with acute, reversible renal failure have been described. It is not known what dose of the drug would be life-threatening.

Should a patient ingest a large quantity of naproxen sodium the stomach may be emptied and usual supportive measures like administration of activated charcoal employed. Hemodialysis does not decrease the plasma concentration of naproxen because of the high degree of its protein binding. There is no specific antidote.

**ACTION AND CLINICAL PHARMACOLOGY**

**Mechanism of Action**
Naproxen like all other nonsteroidal anti-inflammatory drugs (NSAIDs) is an analgesic, antipyretic and anti-inflammatory medication. ALEVE® works at both the site of pain and centrally. The principle mechanism of action relies on the inhibition of prostaglandin synthesis. Prostaglandins are naturally occurring fatty acids derivates that are widely distributed in the tissues, and are involved in the production of pain, fever and inflammation. NSAIDs inhibit prostaglandin synthesis through inhibition of the cyclo-oxygenase enzymes. The anti-inflammatory and analgesic activity of these drugs is based on the concept that prostaglandins sensitize the tissues to pain- and inflammation-producing mediators and the antipyretic activity is assumed to be due to inhibition of prostaglandin synthesis in the hypothalamus induced by infectious states such as the common cold.

**Pharmacodynamics**
In low dose, that is ≤ 660 mg naproxen sodium daily, the analgesic and anti-pyretic activities prevail, while higher doses mostly are necessary for a full anti-inflammatory activity response. Significant naproxen plasma levels and onset of pain relief can be obtained within 20 minutes of intake.

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Single dose</th>
<th>Cmax μg/ml</th>
<th>t½ hours</th>
<th>AUC0-∞ μg/ml.h</th>
<th>Clearance l/h</th>
<th>Volume of distribution (l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>220 mg</td>
<td>35</td>
<td>18</td>
<td>546</td>
<td>0.4</td>
<td>10.0</td>
</tr>
<tr>
<td>440 mg</td>
<td>66</td>
<td>18</td>
<td>1021</td>
<td>0.4</td>
<td>10.6</td>
</tr>
<tr>
<td>2 x 220 mg</td>
<td>53</td>
<td>18.6</td>
<td>852</td>
<td>0.5</td>
<td>14.1</td>
</tr>
</tbody>
</table>
Absorption: naproxen sodium promptly dissolves in the gastric juice to sodium and fine particles of naproxen. Naproxen is rapidly and completely absorbed from the gastrointestinal tract. The peak plasma level (Cmax) of 53-66 g/ml is reached approximately 1-1½ hours after intake of 440mg naproxen sodium. For ALEVE® (Caplets), food can slightly delay naproxen absorption but not the extent, and for ALEVE® Liquid Gels and ALEVE® Back and Body Pain (Capsules), food delays naproxen absorption. The kinetics are dose linear up to 550 mg naproxen sodium twice daily. Plasma concentrations of un-bound circulating naproxen, the active component, of about 10 ng/ml exert analgesic action and correspond to a total naproxen plasma concentration of 15 µg/ml.

Distribution: The volume of distribution of naproxen is small, about 0.1 l/kg. Steady-state concentrations are obtained in two days, and no significant accumulation has been observed. More than 99% of the circulating naproxen is albumin-bound.

Metabolism: Naproxen is either metabolised (cytochrome P450) to 6-0-desmethyl naproxen (6-DMN) and conjugated to glucuronides or left un-metabolised. Naproxen does not induce metabolizing enzymes.

Excretion: Naproxen and its metabolites are primarily excreted via the kidneys (>95%). The elimination half-life of naproxen is about 14 hours. The rate of excretion has been found to coincide closely with the rate of drug disappearance from plasma.

Special Populations and Conditions

Geriatrics: There is no evidence of differential metabolism or excretion in the elderly.

Gender: There is no evidence of differential metabolism or excretion between genders.

Hepatic Insufficiency: In case of severe hepatic insufficiency circulating albumin is decreased giving rise to increased fractions of free and unbound naproxen.

Renal Insufficiency: In case of severe renal insufficiency protein binding is lower giving rise to increased fractions of free and unbound naproxen. In patients with severely reduced glomerular filtration, the rate of urinary excretion may be reduced. Naproxen, in contrast to its non-active metabolite 6-DMN, is not cleared from the body during haemodialysis.

STORAGE AND STABILITY

ALEVE® (Caplets/Tablets): Store at room temperature (15 - 30°C).

ALEVE® Liquid Gels and ALEVE® Back and Body Pain (Capsules): Store at 20-25°C.

SPECIAL HANDLING INSTRUCTIONS

No special requirements
**DOSAGE FORMS, COMPOSITION AND PACKAGING**

One caplet/tablet of ALEVE® contains naproxen sodium 220 mg, of which 20 mg is sodium. The excipients consist of FD&C Blue No. 2, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone, titanium dioxide and talc. Packaging consists of:

- Clear polyvinyl chloride (PVC) blisters with aluminium foil backing packed into an outer carton, containing 10 (1 blister of 10 caplets), 20 (2 blisters of 10 caplets) or 30 caplets (3 blisters of 10 caplets).
- Opaque HDPE bottles containing 24, 50, 100 or 200 caplets packed into an outer carton.
- Opaque HDPE bottles containing 250 caplets
- Opaque HDPE bottles containing 10 tablets
- Professional samples consisting of 1 aluminium sachet containing 1 caplet of naproxen sodium 220 mg.

One capsule of ALEVE® Liquid Gels and ALEVE® Back and Body Pain contains naproxen sodium 220 mg, of which 20 mg is sodium. The excipients consist of FD&C Blue No. 1, gelatin, glycerin, hypromellose, lactic acid, mannitol, polyethylene glycol, povidone, propylene glycol, sorbitan, sorbitol, titanium dioxide, water. Packaging consists of:

- Opaque HDPE bottles containing 20, 40, 80 or 160 capsules packed into an outer carton.
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: Naproxen sodium
Chemical name: 2-Naphthaleneacetic acid, 6-methoxy -α -methyl-, sodium salt, (−).
Molecular formula and molecular mass: C_{14}H_{13}NaO_{3}, 252.24
Structural formula:

![Structural formula](image)

Physicochemical properties: Naproxen sodium is a white to creamy white, crystalline solid, freely soluble in water with a melting point of about 255°C with decomposition.

CLINICAL TRIALS

The published trials regarding the efficacy of ALEVE® consist of 4 studies; three dental extraction trials and 1 trial evaluating the efficacy for short term treatment of knee osteoarthritis.

<table>
<thead>
<tr>
<th>Study Ref. Indication</th>
<th>Trial design &amp; Indication</th>
<th>Duration</th>
<th>Dose (mg) ALEVE® &amp; Comparator</th>
<th>Study subjects</th>
<th>Mean age (StD)</th>
<th>Gender M/F</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kiersch 1993</td>
<td>DB, R, PC, SD Extraction of 1-2 molars</td>
<td>12 hours</td>
<td>ALEVE® 220 mg, Advil 200 mg, Placebo</td>
<td>203 healthy subjects</td>
<td>25 (7)</td>
<td>90/113</td>
</tr>
<tr>
<td>Fricke 1993</td>
<td>DB, R, PC, SD Extraction of 3-4 molars</td>
<td>12 hours</td>
<td>ALEVE® 440 mg, Advil 400 mg, Placebo</td>
<td>201 healthy subjects</td>
<td>24 (7)</td>
<td>77/124</td>
</tr>
<tr>
<td>Kiersch 1994</td>
<td>DB, R, PC, SD Extraction of 3-4 molars</td>
<td>12 hours</td>
<td>ALEVE® 440 mg, Tylenol Extra Strength 1000 mg, Placebo</td>
<td>226 healthy subjects</td>
<td>24 (5)</td>
<td>102/124</td>
</tr>
<tr>
<td>Schiff 2004 [ ]</td>
<td>DB, R, PC, MD Pain and stiffness of knee osteoarthritis</td>
<td>7 days</td>
<td>ALEVE® 440 mg daily (220 mg morning &amp; evening) Advil 1200 mg daily (400 mg TID) placebo</td>
<td>198 patients, ≥ 65 years knee osteoarthritis</td>
<td>72 (5)</td>
<td>75/123</td>
</tr>
</tbody>
</table>

Study demographics and trial design

The dental study population consisted of young, healthy subjects that required extraction of 1 - 4 molars. The knee osteoarthritis (OA) patients were in good general health, of both sexes and any race and had a mean age of 72 years. The diagnosis was verified by standard radiographic criteria applicable for OA stage I-III. All patients had episodic flare ups of OA with at least moderate pain.
Study results

Table 6: Overview of Published Clinical Trial Results

<table>
<thead>
<tr>
<th>Study</th>
<th>Endpoints</th>
<th>Associated values and statistical significance for ALEVE®(A), Comparator(C) and Placebo(P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kiersch 1993</td>
<td>Pain relief up to 12 hours TOTPAR(^1) 21.3 17.8 6.0 NS &lt; 0.001 &lt; 0.001</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Onset of pain relief (median) 1 h 2 h &gt; 12 h NS &lt; 0.001 &lt; 0.001</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Time to re-medication (median) 9.4 h 8.0 h 2 h NS &lt; 0.001 &lt; 0.001</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Re-medication % 51 % 63 % 90 % NS &lt; 0.001 &lt; 0.001</td>
<td></td>
</tr>
<tr>
<td>Fricke 1993</td>
<td>Pain relief up to 12 hours TOTPAR(^1) 19.6 15.8 3.5 NS &lt; 0.001 &lt; 0.001</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Onset of pain relief (median) 0.7 h 0.7 h &gt; 12 h NS &lt; 0.001 &lt; 0.001</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Time to re-medication (median) 7 h 6 h 1.1 h NS &lt; 0.001 &lt; 0.001</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Re-medication % 64 % 78 % 95 % (=0.056) &lt; 0.001 &lt; 0.001</td>
<td></td>
</tr>
<tr>
<td>Kiersch 1994</td>
<td>Pain relief up to 12 hours TOTPAR(^1) 19.1 8.3 5.7 &lt; 0.001 &lt; 0.001 NS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Onset of pain relief (median) 2 h 2 h &gt; 12 h NS &lt; 0.001 &lt; 0.001</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Time to re-medication (median) 9.9 h 3.1 h 2.0 h &lt; 0.001 &lt; 0.001 NS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Re-medication % 56 % 90 % 90 % &lt; 0.001 &lt; 0.001 NS</td>
<td></td>
</tr>
<tr>
<td>Schiff 2004</td>
<td>Symptom improvement on day 7:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Pain at rest 0.8 0.8 0.5 NS &lt; 0.05 NS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Pain on passive motion 0.9 0.9 0.6 NS &lt; 0.05 NS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Pain on weight bearing 1.2 1.0 0.7 NS (=0.064) NS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Stiffness after rest 0.9 0.9 0.4 NS &lt; 0.05 NS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Day pain 1.0 1.0 0.4 NS &lt; 0.01 &lt; 0.01</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Night pain 1.0 0.8 0.5 NS &lt; 0.05 NS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- 50-foot walk time 2.3 s 1.9 s 1.0 s NS &lt; 0.05 NS</td>
<td></td>
</tr>
</tbody>
</table>

s = second(s)
h = hour(s)

The dental pain model, i.e. tooth extraction model, is accepted as the model of choice to establish analgesic efficacy and the results can be extrapolated to other pain states relevant for OTC medication. The studies demonstrate that ALEVE® provides fast and effective pain relief.

For the short-term treatment of pain or stiffness of rheumatic or non-serious arthritic conditions ALEVE® provides clear relief of such states. ALEVE® is clinically proven to relieve arthritis pain. In the comparison ALEVE®/placebo and Advil®/placebo, ALEVE® was superior with respect to alleviating pain experienced at night and stiffness after rest.

\(^1\) Total pain relief (TOTPAR) is an integrated (summary) pain score where pain relief is assessed hourly and represented on a 5-point scale and summed over a period of time (i.e. 12 hours). The 5-point scale consists of a zero score representing no pain relief, 1= a little, 2= some, 3 = a lot and 4= complete pain relief.
In dysmenorrhea ALEVE® compared to placebo demonstrated a significant superiority with respect to total pain relief over 12 hours.

The ALEVE® safety data is derived from clinical trials and post-marketing experience. ALEVE® is as safe on the stomach as Tylenol Extra Strength 500 mg and Advil 200mg if the maximum daily dose and recommended length of use for each product is not exceeded. In the clinical trials the safety profile was comparable to that of Advil, Tylenol Extra Strength and placebo; the most common reactions were GI upset and dizziness, occurring in a small percentage of subjects, with no difference between placebo and active treatments. Serious adverse reactions, like gastrointestinal bleeding or anaphylactic shock, were very rare events (< 0.01%) and occurred in the same degree in ALEVE® and Advil as well as Tylenol Extra Strength treated subjects.

Overall, ALEVE® is an effective analgesic suitable for the treatment of common ailments relevant for self-medication; ALEVE® relieves the daily pain and stiffness of arthritis. ALEVE® relieves morning stiffness and arthritis pain at rest, on passive motion, on weight bearing, pain experienced day or night due to arthritis.

**Pivotal Comparative Bioavailability Study**

A single dose, 2-way comparative bioavailability study of 2 x 220mg Aleve tablets (naproxen sodium) and 2 x 220mg Aleve Liquid Gels and Aleve Back and Body Pain (Capsules) (naproxen sodium) in 26 healthy male and female volunteers was conducted under fasted conditions. A summary of the comparative bioavailability data is presented below:

<table>
<thead>
<tr>
<th>Parameter</th>
<th>ALEVE® Liquid Gels and ALEVE® Back and Body Pain (Capsules) 220 mg</th>
<th>ALEVE® (Tablets) 220mg</th>
<th>% Ratio of Geometric Means</th>
<th>Confidence Interval (90%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC&lt;sub&gt;T&lt;/sub&gt;† (ng.hr/mL)</td>
<td>789789.9 (800415.7 (16.7)</td>
<td>778610.6 (795708.5 (21.4)</td>
<td>101.4</td>
<td>97.9 – 105.1</td>
</tr>
<tr>
<td>AUC&lt;sub&gt;I&lt;/sub&gt; (ng.hr/mL)</td>
<td>838635.9 (851570.5 (18.0)</td>
<td>835610.5 (854934.0 (22.1)</td>
<td>100.4</td>
<td>97.9 – 103.0</td>
</tr>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt; (ng/mL)</td>
<td>52342.3 (53378.26 (19.5)</td>
<td>57339.3 (57818.3 (12.6)</td>
<td>91.3</td>
<td>86.3 – 96.5</td>
</tr>
<tr>
<td>T&lt;sub&gt;max&lt;/sub&gt; (h)</td>
<td>1.62, (72.8)</td>
<td>1.10 (55.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T&lt;sub&gt;1/2&lt;/sub&gt; (h)</td>
<td>18.60 (14.0)</td>
<td>18.55 (17.9)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Aleve (naproxen sodium) Liquid Gels and Aleve (naproxen sodium) Back and Body Pain
220mg, liquid filled soft gelatin capsules
†Aleve (naproxen sodium) Tablets 220mg
€Expressed as the arithmetic mean (CV%) only

DETAILED PHARMACOLOGY
Please refer to Action and Clinical Pharmacology section above.

MICROBIOLOGY
N/A

TOXICOLOGY
The oral LD₅₀ of the drug is 543 mg/kg in rats, 1234 mg/kg in mice, 4110 mg/kg in hamsters and greater than 1000 mg/kg in dogs. No carcinogenic or embryotoxic properties were detected and since the launch of naproxen in the beginning of the 1970's no experience or information has been obtained that could indicate such properties.

Subacute and Chronic Oral Studies
In subacute and chronic oral studies with naproxen in a variety of species, the principle pathologic effect was gastrointestinal irritation and ulceration. The lesions seen were predominantly in the small intestine and ranged from hyperaemia to perforation and peritonitis. Similar results have been reported with other non-steroidal anti-inflammatory agents such as ibuprofen, phenylbutazone, ASA, indomethacin and mefenamic acid.

Nephropathy was seen occasionally in acute and subacute studies in rats, mice and rabbits at high-dose levels of naproxen, but not in rhesus monkeys, miniature pigs or dogs. In the affected species the pathologic changes occurred in the cortex and papilla. Some rats examined 14 days after single oral doses of 230 mg/kg or more of naproxen evidenced necrotic areas of cortical and papillary tissue. Tubular dilation (ectasia) occurred in rabbits dosed orally for 14 days with 200mg/kg/day or more of naproxen. An examination of unfixed renal tissue from rabbits so-treated was conducted and revealed the presence of diffraction patterns similar to that of crystalline naproxen. This suggests that the ectasia observed was a physical response to deposition of excreted naproxen within the tubules.

In mice given oral doses of 120 mg/kg/day or more of naproxen for 6 months, the kidneys were characterized by a low but non-dosage-related incidence of cortical sclerosis and papillary tip necrosis. Chronic administration of high doses of naproxen to mice appears to be associated with exacerbation of spontaneous murine nephropathy.

Rhesus monkeys were administered daily doses of 7, 20, or 60 mg/kg and the monkeys received these daily doses for the next six months. No evidence of drug-related pathology was seen in this study. In a 1 year study in rhesus monkeys at daily doses of 100, 140, 180 mg/kg renal lesions consistent with those described for analgesic nephropathy were observed. The severity of the lesions was generally dose related.
A similar catalogue of renal responses has been reported in the laboratory animals treated with a variety of non-steroidal anti-inflammatory agents.

A wide range of susceptibility to gastrointestinal lesions from administration of naproxen was evident in the various species tested. For example, 30mg/kg/day was tolerated well by rats for 90 days, but the same dose was ulcerogenic when administered for 6 months. Rhesus monkeys and miniature swine exhibited no significant pathology when dosed with naproxen at 45 mg/kg/day for 30 days. This dose of naproxen was also tolerated by miniature swine without obvious evidence of adverse effects when administered daily for 1 year. In rhesus monkeys doses as high as 120 mg/kg/day (60 mg/kg b.i.d.) for 6 months produced no clinical or histopathological evidence of gastrointestinal irritation although occult blood in the feces occurred more frequently in these animals compared to controls. Daily administration of naproxen to rhesus monkeys for one year was associated with mild gastric irritation in a few animals receiving 100, 140 or 180 mg/kg. In rabbits the maximum tolerated repeated oral dose is 80 to 100 mg/kg/day. Mice survived oral daily doses of 240 mg/kg/day for 6 months. In dogs, on the other hand, 5.0 mg/kg/day approaches the maximum tolerated dose. This peculiar canine susceptibility to gastrointestinal effects of non-steroidal anti-inflammatory agents has also been shown with indomethacin and ibuprofen.

In dogs naproxen exhibits a considerably longer plasma half-life than it does in rats, guinea pigs; miniature swine, monkeys, and man. The same observation has been made with ibuprofen in dogs compared to rats and man. In addition, in the species listed, only the dog excretes significant amounts of administered naproxen in the feces (50%). In the rat, guinea pigs, miniature swine, monkey and man, 86-90% of the administered drug is excreted in the urine. The suggested enteroheptic circulation of naproxen in the dog (as judged by fecal excretion) most likely is a major factor in the susceptibility of the dog to gastrointestinal irritation by this compound.

In subacute and chronic toxicity studies, other pathological changes were often seen which were considered to be clearly secondary to the effects of naproxen on the gastrointestinal tract. These consisted of peritoneal inflammation and adhesions, mesenteric lymphadenopathy, decreased haemoglobin and hematocrit levels, leucocytosis, evidence of stimulated hematopoeisis and elevated plasma glutamic oxaloacetic transaminase.

As noted above, gastrointestinal pathology in laboratory animals is a finding common to non-steroidal anti-inflammatory agents.

Ophthalmic examinations were made in the two year rat study and the one year monkey study. No eye changes considered to be drug related were noted except for the observation of pale irides in the rats. This was secondary to anemia as a result of gastrointestinal blood loss and did not represent a toxic effect of naproxen on the eye.

Plasma levels of naproxen were measured in monkeys dosed for one year with 100, 140 or 180 mg/kg/day naproxen. Plasma levels after 1 week of dosing were not significantly different form
those after 12 months of dosing. As judged by these results there was no evidence of tachyphylaxis or accumulation over the 1 year dosing period.

Moderate weight loss of the male secondary sex glands occurred in some studies in naproxen-treated rats and dogs. Histopathologically the affected glands in some instances exhibited atrophic and/or hypoplastic changes characterized by decreased secretory material. A possible estrogenic action of naproxen as a causative factor seems highly unlikely since in standard bioassay procedures the drug exhibited no estrogenic activity.

Daily doses of naproxen as high as 30 mg/kg administered for 60 days before mating had no effect on fertility and reproductive performance of male rats. These results reflect the physiological integrity of the entire male reproductive apparatus after administration of naproxen throughout the spermatogenic cycle.

**Teratology**

In embryotoxicity studies no skeletal or visceral anomalies or pathologic changes were induced in the fetuses of pregnant rats and rabbits treated during organogenesis with daily oral doses of naproxen up to 20 mg/kg nor in mice similarly treated with 30 or 50 mg/kg. In these studies there were also no significant differences from controls in the number of live fetuses, resorptions, fetal weights or ano-genital distances. In another mouse study no malformations were observed with administration of 60 or 120 mg/kg of naproxen although there was a slight reduction in numbers of live fetuses in both dose groups and in fetal body weight in the high dose group.

**Reproductive Studies**

Daily oral administration of 15, 30 or 60 mg/kg of naproxen to female rabbits from 2 weeks before mating until day 20 of pregnancy did not affect fertility, gestation, or the numbers of live fetuses.

In a peri- and post-natal study in rats, oral doses of naproxen up to 20 mg/kg administered daily during the last part of pregnancy through weaning did not result in adverse effects in viability of pups, lactation index, sex ratio or weight gain of offspring. However, there was a slight increase in gestation length at the 10 and 20 mg/kg dose levels; and, at the 10 mg/kg dose level, there was a significant increase in stillbirths.

The mechanism of this phenomenon in the rats is not entirely clear at present. It is possible that difficulties in delivery in naproxen-treated rats reflect a general underlying maternal debility induced by increased susceptibility of the pregnant animals to gastrointestinal ulceration and subsequent peritonitis. Such an observation has been reported with ibuprofen. Pregnant animals were reported to be 9 times more susceptible to the ulcerogenic effects of that compound than were non-pregnant animals. Similarly, with naproxen, gastrointestinal lesions in non-pregnant paired drug-treated controls were found to occur less frequently and were less extensive than those in pregnant rates treated daily from day 15 of pregnancy through term.

More recent evidence, however, suggests that inhibition of prostaglandin synthesis by non-steroidal anti-inflammatory compounds may be related to decreased uterine contractility. Thus,
the onset of labour in a rat model system can be delayed with naproxen administration without causing maternal or fetal deaths in excess of that seen in controls. Since it has been shown that naproxen inhibits prostaglandin synthesis in vitro, it has been suggested that the effects of naproxen on uterine contractility are mediated through that mechanism.

Maternal and fetal deaths seen in naproxen-treated rats were, therefore, apparently related to dystocia rather than to a direct toxic effect of the compound. Naproxen is not unique in this regard since comparable results were obtained in the rat with other commonly used non-steroidal anti-inflammatory agents (ASA, indomethacin, mefenamic acid and phenylbutazone). Similar results have been suggested in reports of other animal studies with ibuprofen.

In a fertility and reproduction study in mice, the dams were dosed daily with 12, 36 or 108 mg/kg from 14 days prior to mating through weaning. At the highest dose level, there was an increase in maternal deaths which was reflected in decreased 21 day survival and lactation indices. There were no other changes in the parameters examined. In a similar study in rats, daily doses were 2, 10 or 20 mg/kg from 14 days before mating through weaning. Other than decreased survival to weaning which appeared due to poor maternal care in pups born to high dose dams, there were no differences between control and treated groups. One mid and one high dose dam died during labour due to delayed parturition.

The toxicity of naproxen in juvenile animals was compared to that in adult animals. The results of single oral dose LD$_{50}$ studies in weanling rats and mice, run simultaneously with studies in adult animals, revealed no significant differences in the values obtained with mature and immature animals of both species.

An additional study with juvenile mice consisted of two parts. Weaning animals were treated daily for one month with a pediatric formulation of naproxen. At the end of the treatment period a portion of the animals were examined for pathologic changes. The remaining animals were allowed to reach maturity and breed.

The usual gastroenteropathy characteristic for non-steroidal anti-inflammatory agents was observed in some high dose (135 mg/kg) mice. Naproxen administration for the first post-weaning month of life did not compromise in any way the later fertility or reproductive capacity of mice so-treated.

**Mutagenicity**

Mutagenicity tests were performed with naproxen using 5 strains of bacteria and one of yeast. The test was carried out with and without mammalian microsomal activation. Naproxen was also tested in the mouse lymphoma assay. Naproxen was not mutagenic.

**Carcinogenicity**

To evaluate the carcinogenic potential of naproxen, the compound was administered in the feed to rats for up to 2 years. Naproxen did not reveal any carcinogenic potential in rats.
©ALEVE and Strength to last up to 12 hours are trademarks of Bayer Consumer Care AG, used under licence. Bayer Inc., Toronto, Ontario M9W 1G6.
All other trademarks are owned by their respective owners.
REFERENCES


Clausen E. Histological changes in rabbit kidneys induced by phenacetin and Acetylsalicylic acid. Lancet. 1964 Jul 18;18;123-4.


Drugdex. Naproxen. Micromex 2004


Frishman WH. Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am J Cardiol. 2002 Mar 21;89(6A):18D-25D.


Health Canada: Chapter 3: nutrition intervention in hepatitis C. Hepatitis C: Nutrition care Canadian guidelines for health care providers.

Health Canada: Problem solver in hypertension management and control. The health heart kit. Helping your patients reduce their risk.


Methotrexate Drugdex Micromex 2004


PART III: CONSUMER INFORMATION

ALEVE®
(Naproxen Sodium Tablets, USP, 220 mg)

This leaflet is part III of a three-part "Product Monograph" published when ALEVE® was approved for sale in Canada and is designed specifically for Consumers. This is a summary and will not tell you everything about ALEVE®. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:
Trust ALEVE® for providing fast and effective relief of pain such as arthritis pain and pain of inflammation. ALEVE® relieves arthritic conditions such as stiffness, pain experienced day or night due to arthritis or stiffness of rheumatic conditions. ALEVE® also relieves joint and body pain, muscular ache, muscle sprains and strains, backache, minor aches, headaches, migraine pain, menstrual cramps, pain of minor surgery, toothaches, pain of dental extractions, pain associated with the common cold and reduces fever. Clinical studies show long lasting relief for up to 12 hours.

What it does:
ALEVE® is a pain reliever and fever reducer. ALEVE® works both at the site of pain and in your central nervous system. ALEVE® starts to work fast and treats pain where it starts.

When it should not be used:
Do not take ALEVE® if you:
- are allergic to naproxen, naproxen sodium, or any ingredient in the formulation
- are allergic to acetylsalicylic acid (ASA), other salicylates or other non-steroidal anti-inflammatory drugs (NSAIDs)
- have an active peptic ulcer, a history of recurrent ulceration, or active gastrointestinal bleeding
- have inflammatory bowel disease
- have liver disease (active or severe)
- have kidney disease (severe or worsening)
- are in your third trimester of pregnancy

What the medicinal ingredient is:
Naproxen sodium 220 mg

What the important non-medicinal ingredients are:
FD&C Blue No. 2, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone, titanium dioxide and talc

What dosage forms it comes in:
ALEVE® comes in 220mg Caplets and Tablets

WARNINGS AND PRECAUTIONS

BEFORE you use ALEVE® talk to your doctor or pharmacist if you have or have had:
- asthma or a similar respiratory illness
- nasal polyps
- itchy skin and hives
- history of gastrointestinal disease
- high blood pressure
- a blood clotting disorder
- heart disease/failure
- any other serious disease

OR if you are:
- trying to conceive
- in your first or second trimester of pregnancy
- are nursing

INTERACTIONS WITH THIS MEDICATION

BEFORE you use ALEVE® talk to your doctor or pharmacist if are taking any other drug especially:
- Anticoagulants (to decrease blood clotting)
- Antihypertensive drugs for your heart (including ACE inhibitors and beta-blockers)
- Diuretics (“water pills”)
- Cyclosporine
- Glucocorticoids
- Lithium
- Methotrexate
- low dose ASA for doctor supervised daily preventative therapy (e.g. ASPIRIN® 81mg)
- NSAIDs or other pain medications (e.g. ibuprofen, acetaminophen)

Taking ALEVE® with a meal may slightly delay its absorption.

PROPER USE OF THIS MEDICATION

Usual dose:
Adults (12-65 years): 1 caplet/tablet every 8 - 12 hours. Adults over 65 years 1 caplet/tablet every 12 hours. Do not take more than 2 caplets/tablets in a 24 hour period. Drink a full glass of water with each dose. Do not use in children under 12 years. Consult a doctor if fever lasts more than 3 days or pain lasts longer than 5 days or if your symptoms change.

Overdose:
In case of drug overdose, contact a healthcare practitioner (or doctor), hospital emergency department or regional poison control centre, even if there are no symptoms.
SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Like all medicines, ALEVE® may occasionally produce unwanted side effects. Stop use and contact a doctor or pharmacist if you experience: heartburn, nausea, vomiting, ringing or buzzing in the ears, bloating, diarrhea or constipation.

This is not a complete list of side effects. For any unexpected effects while taking ALEVE®, contact your doctor or pharmacist.

SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Stop use and get emergency medical attention IMMEDIATELY if you experience: difficulty breathing, facial swelling, hives, rash or itching.

Stop use and contact a doctor or pharmacist if you experience: black stools, severe abdominal pain, any change in vision or fluid retention.

If you become drowsy, dizzy or lightheaded do not drive or operate machinery and contact your doctor or pharmacist.

HOW TO STORE IT

● CAUTION: This package contains enough drug to seriously harm a child. Keep out of children’s reach.

Store at 15-30°C (59-86°F).

REPORTING SUSPECTED SIDE EFFECTS

You can help improve the safe use of health products for Canadians by reporting serious and unexpected side effects to Health Canada. Your report may help to identify new side effects and change the product safety information.

3 ways to report:

● Online at MedEffect (http://hc-sc.gc.ca/dhp-mps/medeff/index-eng.php);

● By calling 1-866-234-2345(toll-free);

● By completing a Consumer Side Effect Reporting Form and sending it by:
  - Fax to 1-866-678-6789 (toll-free), or
  - Mail to: Canada Vigilance Program
    Health Canada, Postal Locator 0701E
    Ottawa, ON K1A 0K9


NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.
PART III: CONSUMER INFORMATION

ALEVE® Liquid Gels
(Naproxen Sodium Capsules, 220 mg)

This leaflet is part III of a three-part "Product Monograph" published when ALEVE® Liquid Gels was approved for sale in Canada and is designed specifically for Consumers. This is a summary and will not tell you everything about ALEVE® Liquid Gels. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:
Trust ALEVE® Liquid Gels for providing fast and effective relief of pain such as arthritis pain and pain of inflammation. ALEVE®LIQUID GELS relieves arthritic conditions such as stiffness, pain experienced day or night due to arthritis or stiffness of rheumatic conditions. ALEVE® Liquid Gels also relieves joint and body pain, muscular ache, muscle sprains and strains, backache, minor aches, headaches, migraine pain, menstrual cramps, pain of minor surgery, toothaches, pain of dental extractions, pain associated with the common cold and reduces fever. Clinical studies show long lasting relief for up to 12 hours.

What it does:
ALEVE® Liquid Gels is a pain reliever and fever reducer. ALEVE® Liquid Gels works both at the site of pain and in your central nervous system. ALEVE® Liquid Gels starts to work fast and treats pain where it starts.

When it should not be used:
Do not take ALEVE® Liquid Gels if you:
- are allergic to naproxen, naproxen sodium, or any ingredient in the formulation
- are allergic to acetylsalicylic acid (ASA), other salicylates or other non-steroidal anti-inflammatory drugs (NSAIDs)
- have an active peptic ulcer, a history of recurrent ulceration, or active gastrointestinal bleeding
- have inflammatory bowel disease
- have liver disease (active or severe)
- have kidney disease (severe or worsening)
- are in your third trimester of pregnancy

What the medicinal ingredient is:
Naproxen sodium 220 mg

What the important non-medicinal ingredients are:
FD&C Blue No. 1, gelatin, glycerin, hypromellose, lactic acid, mannitol, polyethylene glycol, povidone, propylene glycol, sorbitan, sorbitol, titanium dioxide, water

What dosage forms it comes in:
Capsule: 220 mg

WARNINGS AND PRECAUTIONS

BEFORE you use ALEVE® Liquid Gels talk to your doctor or pharmacist if you have or have had:
- asthma or a similar respiratory illness
- nasal polyps
- itchy skin and hives
- history of gastrointestinal disease
- high blood pressure
- a blood clotting disorder
- heart disease/failure
- any other serious disease

OR if you are:
- trying to conceive
- in your first or second trimester of pregnancy
- are nursing

INTERACTIONS WITH THIS MEDICATION

BEFORE you use ALEVE® Liquid Gels talk to your doctor or pharmacist if are taking any other drug especially:
- Anticoagulants (to decrease blood clotting)
- Antihypertensive drugs for your heart (including ACE inhibitors and beta-blockers)
- Diuretics ("water pills")
- Cyclosporine
- Glucocorticoids
- Lithium
- Methotrexate
- low dose ASA for doctor supervised daily preventative therapy (e.g. ASPIRIN® 81mg)
- NSAIDs or other pain medications (e.g. ibuprofen, acetaminophen)

Taking ALEVE® Liquid Gels with a meal will delay its absorption.

PROPER USE OF THIS MEDICATION

Usual dose:
Adults (12-65 years): 1 capsule every 8 - 12 hours. Adults over 65 years 1 capsule every 12 hours. Do not take more than 2 capsules in a 24 hour period. Drink a full glass of water with each dose. Do not use in children under 12 years. Consult a doctor if fever lasts more than 3 days or pain lasts longer than 5 days or if your symptoms change.

Overdose:
In case of drug overdose, contact a healthcare practitioner (or doctor), hospital emergency department or regional poison control centre, even if there are no symptoms.
SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Like all medicines, ALEVE® Liquid Gels may occasionally produce unwanted side effects. Stop use and contact a doctor or pharmacist if you experience: heartburn, nausea, vomiting, ringing or buzzing in the ears, bloating, diarrhea or constipation.

This is not a complete list of side effects. For any unexpected effects while taking ALEVE® Liquid Gels, contact your doctor or pharmacist.

SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Stop use and get emergency medical attention IMMEDIATELY if you experience: difficulty breathing, facial swelling, hives, rash or itching.

Stop use and contact a doctor or pharmacist if you experience: black stools, severe abdominal pain, any change in vision or fluid retention.

If you become drowsy, dizzy or lightheaded do not drive or operate machinery and contact your doctor or pharmacist.

HOW TO STORE IT

● CAUTION: This package contains enough drug to seriously harm a child. Keep out of children’s reach.

Store at 20-25°C

REPORTING SUSPECTED SIDE EFFECTS

You can help improve the safe use of health products for Canadians by reporting serious and unexpected side effects to Health Canada. Your report may help to identify new side effects and change the product safety information:

3 ways to report:

● Online at MedEffect (http://hc-sc.gc.ca/dhp-mps/medeff/index-eng.php);
● By calling 1-866-234-2345 (toll-free), or
● By completing a Consumer Side Effect Reporting Form and sending it by:
  - Fax to 1-866-678-6789 (toll-free), or
  - Mail to: Canada Vigilance Program
    Health Canada, Postal Locator 0701E
    Ottawa, ON K1A 0K9

● Postage paid labels and the Consumer Side Effect Reporting Form are available at MedEffect (http://hc-sc.gc.ca/dhp-mps/medeff/index-eng.php)

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide material advice.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found at: http://www.bayer.ca.

This leaflet was prepared by Bayer Inc.
Last revised: January 8th, 2015

®ALEVE and Strength To Last Up To 12 Hours are trademarks of Bayer Consumer Care AG, used under licence. Bayer Inc., Consumer Care Toronto, Ontario M9W 1G6.
®Bayer, Bayer Cross and ASPIRIN are registered trademarks of Bayer AG, used under licence.
www.ALEVE.ca

© 2015, Bayer Inc.
PART III: CONSUMER INFORMATION

ALEVE® Back and Body Pain
(Naproxen Sodium Capsules, 220 mg)

This leaflet is part III of a three-part "Product Monograph" published when ALEVE® Back and Body Pain was approved for sale in Canada and is designed specifically for Consumers. This is a summary and will not tell you everything about ALEVE® Back and Body Pain. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:
Trust ALEVE® Back and Body Pain for providing fast and effective relief of pain such as body pain, muscular ache, muscle sprains and strains, backache, minor aches, headaches, and migraine pain.

ALEVE® Back and Body Pain also relieves arthritis pain and pain of inflammation, arthritic conditions such as stiffness, pain experienced day or night due to arthritis or stiffness of rheumatic conditions, joint pain, menstrual cramps, pain of minor surgery, toothaches, pain of dental extractions, pain associated with the common cold and reduces fever. Clinical studies show long lasting relief for up to 12 hours.

What it does:
ALEVE® Back and Body Pain is a pain reliever and fever reducer. ALEVE® Back and Body Pain works both at the site of pain and in your central nervous system. ALEVE® Back and Body Pain starts to work fast and treats pain where it starts.

When it should not be used:
Do not take ALEVE® Back and Body Pain if you:
- are allergic to naproxen, naproxen sodium, or any ingredient in the formulation
- are allergic to acetylsalicylic acid (ASA), other salicylates or other non-steroidal anti-inflammatory drugs (NSAIDs)
- have an active peptic ulcer, a history of recurrent ulceration, or active gastrointestinal bleeding
- have inflammatory bowel disease
- have liver disease (active or severe)
- have kidney disease (severe or worsening)
- are in your third trimester of pregnancy

What the medicinal ingredient is:
Naproxen sodium 220 mg

What the important non-medicinal ingredients are:
FD&C Blue No. 1, gelatin, glycerin, hypromellose, lactic acid, mannitol, polyethylene glycol, povidone, propylene glycol, sorbitan, sorbitol, titanium dioxide, water

What dosage forms it comes in:
Capsule: 220 mg

WARNINGS AND PRECAUTIONS

BEFORE you use ALEVE® Back and Body Pain talk to your doctor or pharmacist if you have or have had:
- asthma or a similar respiratory illness
- nasal polyps
- itchy skin and hives
- history of gastrointestinal disease
- high blood pressure
- a blood clotting disorder
- heart disease/failure
- any other serious disease

OR if you are:
- trying to conceive
- in your first or second trimester of pregnancy
- are nursing

INTERACTIONS WITH THIS MEDICATION

BEFORE you use ALEVE® Back and Body Pain talk to your doctor or pharmacist if are taking any other drug especially:
- Anticoagulants (to decrease blood clotting)
- Antihypertensive drugs for your heart (including ACE inhibitors and beta-blockers)
- Diuretics ("water pills")
- Cyclosporine
- Glucocorticoids
- Lithium
- Methotrexate
- low dose ASA for doctor supervised daily preventative therapy (e.g. ASPIRIN® 81mg)
- NSAIDs or other pain medications (e.g. ibuprofen, acetaminophen)

Taking ALEVE® Back and Body Pain with a meal will delay its absorption.

PROPER USE OF THIS MEDICATION

Usual dose:
Adults (12-65 years): 1 capsule every 8 - 12 hours. Adults over 65 years 1 capsule every 12 hours. Do not take more than 2 capsules in a 24 hour period. Drink a full glass of water with each dose. Do not use in children under 12 years. Consult a doctor if fever lasts more than 3 days or pain lasts longer than 5 days or if your symptoms change.

Overdose:
In case of drug overdose, contact a healthcare practitioner (or doctor), hospital emergency department or regional poison control centre, even if there are no symptoms.

### SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Like all medicines, ALEVE® Back and Body Pain may occasionally produce unwanted side effects. Stop use and contact a doctor or pharmacist if you experience: heartburn, nausea, vomiting, ringing or buzzing in the ears, bloating, diarrhea or constipation.

*This is not a complete list of side effects. For any unexpected effects while taking ALEVE® Back and Body Pain, contact your doctor or pharmacist.*

### SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Stop use and get emergency medical attention IMMEDIATELY if you experience: difficulty breathing, facial swelling, hives, rash or itching.

Stop use and contact a doctor or pharmacist if you experience: black stools, severe abdominal pain, any change in vision or fluid retention.

If you become drowsy, dizzy or lightheaded do not drive or operate machinery and contact your doctor or pharmacist.

### HOW TO STORE IT

- **CAUTION:** This package contains enough drug to seriously harm a child. Keep out of children’s reach.

Store at 20-25°C

### REPORTING SUSPECTED SIDE EFFECTS

You can help improve the safe use of health products for Canadians by reporting serious and unexpected side effects to Health Canada. Your report may help to identify new side effects and change the product safety information:

**3 ways to report:**

- [Online](http://hc-sc.gc.ca/dhp-mps/medeff/index-eng.php);
- By calling 1-866-234-2345 (toll-free), or
- By completing a Consumer Side Effect Reporting Form and sending it by:
  - Fax to 1-866-678-6789 (toll-free), or
  - Mail to: Canada Vigilance Program
  Health Canada, Postal Locato 0701E
  Ottawa, ON K1A 0K9
- Postage paid labels and the Consumer Side Effect Reporting Form are available at [MedEffect](http://hc-sc.gc.ca/dhp-mps/medeff/index-eng.php)

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide material advice.*

### MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found at:

http://www.bayer.ca.

This leaflet was prepared by Bayer Inc.

Last revised: January 8th, 2015

©ALEVE and Strength To Last Up To 12 Hours are trademarks of Bayer Consumer Care AG, used under licence. Bayer Inc., Consumer Care Toronto, Ontario M9W 1G6.

©Bayer, Bayer Cross and ASPIRIN are registered trademarks of Bayer AG, used under licence.

www.ALEVE.ca

© 2015, Bayer Inc.